Variable | Northwest Territories | Nunavut | Nunavut without Iqaluit | Kitikmeot | Kivalliq | Qikiqtaaluk | Qikiqtaaluk without Iqaluit | Nunavik |
---|---|---|---|---|---|---|---|---|
Total births in 2009 | 739 | 816 | 701 | 114 | 245 | 457 | 342 | 250 |
Healthy newborns | 679.9 | 750.7 | 644.9 | 104.9 | 225.4 | 420.4 | 314.6 | 230 |
Rate of RSV infection in healthy infants < 6 mo of age January to June 2009, per 1000 live births | 23.5 | 111.9 | 127.1 | 324.1 | 124.2 | 52.3 | 63.6 | 208.7 |
Base case: no prophylaxis, RSV-related admissions in healthy term infants admitted Jan. 1 to June 30, 2009 | ||||||||
No. of RSV-related admissions among infants < 6 mo of age | 8 | 42 | 41 | 17 | 14 | 11 | 10 | 24 |
No. of RSV-related admissions among infants ≥ 6 mo of age | 0 | 10 | 10 | 5 | 4 | 1 | 1 | 6 |
Total cost of RSV-related admissions among infants < 6 mo of age, $ | 2 476 100 | 2 461 523 | 1 255 638 | 964 915 | 255 547 | 240 971 | 571 929 | |
Total cost of RSV-related admissions among infants ≥ 6 mo of age, $ | 0 | 395 037 | 395 038 | 240 727 | 129 688 | 24 622 | 24 622 | 60 210 |
Total cost of all RSV-related admissions, $ | 177 256 | 2 871 137 | 2 856 561 | 1 496 365 | 1 094 603 | 280 169 | 265 593 | 632 139 |
Scenario B: palivizumab prophylaxis of healthy term infants up to 5 months of age, with 96% risk reduction | ||||||||
No. of RSV-related admissions among infants < 6 mo (received prophylaxis) | 0.3 | 1.7 | 1.6 | 0.7 | 0.6 | 0.4 | 0.4 | 1.0 |
No. of RSV-related admissions among infants ≥ 6 mo of age (did not receive prophylaxis) | 0 | 10 | 10 | 5 | 4 | 1 | 1 | 6 |
Costs of admissions of infants < 6 mo of age, $ | 7090 | 99 044 | 98 461 | 50 226 | 38 597 | 10 222 | 9639 | 22 877 |
Cost of admissions of infants ≥ 6 mo of age, $ | 0 | 395 037 | 395 038 | 240 727 | 129 688 | 24 622 | 24 622 | 60 210 |
Total cost of all RSV-related admissions, $ | 7090 | 494 081 | 493 499 | 290 953 | 168 285 | 34 844 | 34 261 | 83 087 |
Estimated cost of palivizumab, $ | 2 683 762 | 2 963 231 | 2 545 607 | 414 071 | 889 719 | 1 659 441 | 1 241 817 | 907 877 |
Total costs (palivizumab + all RSV-related admissions), $* | 2 690 852 | 3 457 312 | 3 039 106 | 705 024 | 1 058 004 | 1 694 285 | 1 276 078 | 990 964 |
Scenario B v. base case | ||||||||
Incremental cost for RSV prophylaxis, $ | 2 513 597 | 586 175 | 182 545 | -791 342 | -36 599 | 1 414 116 | 1 010 486 | 358 825 |
Incremental RSV-related admissions avoided | 7.7 | 30.3 | 29.4 | 11.3 | 9.4 | 9.6 | 8.6 | 17 |
ICER per RSV-related admission avoided, $ | 326 441 | 14 545 | 4633 | -48 549 | -2731 | 133 407 | 105 259 | 15 601 |
NNT to prevent 1 RSV-related admission among infants < 6 mo of age | 44.3 | 9.3 | 8.2 | 3.2 | 8.4 | 19.9 | 16.4 | 5.0 |
Note: ICER = incremental cost-effectiveness ratio, NNT = number needed to treat, RSV = respiratory syncytial virus.
*Include the revised cost with 96% risk reduction if < 6 months of age, and full costs if ≥ 6 months of age (no prophylaxis).